Eric Easom is CEO at AN2 Therapeutics, Inc. (ANTX). They have made 8 open-market trades across 1 company since 2022, most recently 2026-02-20.
CIK 0001914503
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $115K since 2023, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ANTX | 368,630 | $1.2M |
Shares reported on the most recent Form 4, priced at the 2026-02-23 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANTX | BUY | 2025-06-02 | 2025-06-03 | $1.07 | $11K | -3.6% | -5.4% | +3.6% |
| ANTX | BUY | 2024-11-18 | 2024-11-18 | $1.00 | $50K | +62.1% | +27.2% | +10.7% |
| ANTX | SELL · 10b5-1 | 2024-01-02 | 2024-01-04 | $20.09 | $112K | +7.8% | +8.5% | -82.6% |
| ANTX | BUY | 2023-05-15 | 2023-05-15 | $5.38 | $54K | +1.6% | +35.9% | +54.0% |
| ANTX | SELL | 2022-11-10 | 2022-11-14 | $15.32 | $136K | -25.3% | -33.0% | -3.8% |
| ANTX | SELL | 2022-11-08 | 2022-11-09 | $15.60 | $426K | -25.5% | -43.4% | -3.1% |
| ANTX | SELL | 2022-11-03 | 2022-11-07 | $15.83 | $1.0M | -18.2% | -46.4% | -8.3% |
| ANTX | SELL · 10b5-1 | 2022-10-31 | 2022-11-02 | $15.27 | $65K | -0.6% | -34.9% | -17.9% |
| ANTX | SELL · 10b5-1 | 2022-10-27 | 2022-10-28 | $15.19 | $40K | +5.9% | -30.7% | -17.9% |
| ANTX | SELL | 2022-10-24 | 2022-10-26 | $15.74 | $214K | +11.8% | -27.3% | -34.5% |
| ANTX | SELL | 2022-10-20 | 2022-10-24 | $16.46 | $660K | -2.9% | -34.7% | -39.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.